NIR FME of Labelled Vedolizumab to Elucidate the Mechanism of Action and Predicting Response in IBD Patients.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colitis Ulcerative
- Crohn Disease
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
See brief summary
See brief summary
Tracking Information
- NCT #
- NCT04112212
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: W.B. Nagengast, MD, PhD, PharmD University Medical Center Groningen